Clinical trial
Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft…
NCT00276055 · New Mexico Cancer Research Alliance, Other · Completed
Key facts
| NCT number | NCT00276055 |
|---|---|
| Title | Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma |
| Official title | Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma |
| Lead sponsor | New Mexico Cancer Research Alliance, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | Gemcitabine, Docetaxel and Bevacizumab |
| Enrollment | 38 |
| Start date | Nov 1, 2005 |
| Primary completion | Nov 1, 2010 |
| Completion | Nov 1, 2010 |
| First posted | Jan 12, 2006 |
| Last update posted | Jun 19, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: